| 1. |
Kontoyiannis DP, Walsh TJ. Mucormycosis[J]. N Engl J Med, 2026, 394(7): 684-698.
|
| 2. |
中國醫藥教育協會真菌病專業委員會, 中國毛霉病專家共識工作組. 中國毛霉病臨床診療專家共識(2022)[J]. 中華內科雜志, 2023, 62(6): 597-605.Medical Mycology Society of Chinese Medicine and Education Association, Chinese Mucormycosis Expert Consensus Group. Expert consensus on diagnosis and management of mucormycosis in China[J]. Chin J Intern Med, 2023, 62(6): 597-605.
|
| 3. |
Danion F, Coste A, Le Hyaric C, et al. What is new in pulmonary mucormycosis[J/OL]. J Fungi (Basel), 2023, 9(3): 307. DOI: 10.3390/jof9030307.
|
| 4. |
Morrissey CO, Kim HY, Garnham K, et al. Mucorales: a systematic review to inform the World Health Organization priority list of fungal pathogens[J/OL]. Med Mycol, 2024, 62(6): myad130. DOI: 10.1093/mmy/myad130.
|
| 5. |
Agrawal R, Yeldandi A, Savas H, et al. Pulmonary mucormycosis: risk factors, radiologic findings, and pathologic correlation[J]. Radiographics, 2020, 40(3): 656-666.
|
| 6. |
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J/OL]. Lancet Infect Dis, 2019, 19(12): e405-e421. DOI: 10.1016/S1473-3099(19)30312-3.
|
| 7. |
中華醫學會呼吸病學分會. 侵襲性肺真菌病診斷與治療指南(2025年版)[J]. 中華結核和呼吸雜志, 2025, 48(12): 1104-1126.Chinese Thoracic Society. Clinical practice guidelines for the diagnosis and management of invasive pulmonary fungal diseases (2025 Edition)[J]. Chin J Tuberc Respir Dis, 2025, 48(12): 1104-1126.
|
| 8. |
Jindal P, Kalra S. Surgical management of pulmonary mucormycosis[J]. Thorac Surg Clin, 2026, 36(3): 323-335.
|
| 9. |
Muthu V, Agarwal R, Dhooria S, et al. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis[J]. Clin Microbiol Infect, 2021, 27(4): 538-549.
|
| 10. |
Coste A, Conrad A, Porcher R, et al. Improving diagnosis of pulmonary mucormycosis: leads from a contemporary national study of 114 cases[J]. Chest, 2023, 164(5): 1097-1107.
|
| 11. |
Wan J, Liu T, Li F, et al. Diagnosis, clinical features, and mortality risk factors in a Chinese cohort with pulmonary mucormycosis[J/OL]. PLoS One, 2025, 20(5): e0323624. DOI: 10.1371/journal.pone.0323624.
|
| 12. |
尹艾若, 王海燕, 苑鑫, 等. 肺毛霉病臨床特征及預后因素的多中心回顧性分析[J]. 解放軍醫學院學報, 2023, 44(12): 1357-1363, 1371.Yin AR, Wang HY, Yuan X, et al. Clinical features and prognostic factors of pulmonary mucormycosis: a multicenter retrospective analysis[J]. Acad J Chin PLA Med Sch, 2023, 44(12): 1357-1363, 1371.
|
| 13. |
劉智博, 張芳, 梁朝陽, 等. 手術與未手術肺毛霉病患者29例臨床特征分析[J]. 中華結核和呼吸雜志, 2024, 47(10): 946-954.Liu ZB, Zhang F, Liang CY, et al. Clinical characteristics of 29 cases of pulmonary mucormycosis treated with and without surgery[J]. Chin J Tuberc Respir Dis, 2024, 47(10): 946-954.
|
| 14. |
Yang C, Mei C, Cao T, et al. Clinical features, management, and outcomes of pulmonary mucormycosis: a decade-long retrospective study from a single center in central China[J/OL]. Front Med (Lausanne), 2026, 13: 1844463. DOI: 10.3389/fmed.2026.1844463.
|
| 15. |
Liu J, Yu L, Ma X, et al. Clinical characteristics, radiological, and outcomes of mucormycosis: a 14-year retrospective study from Southern China[J/OL]. Mycoses, 2025, 68(9): e70110. DOI: 10.1111/myc.70110.
|
| 16. |
郭雨霏, 詹慶元, 黃琳娜. 肺毛霉病47例臨床特征、診治策略及預后因素分析[J]. 中華內科雜志, 2026, 65(7): 734-742.Guo YF, Zhan QY, Huang LN. Clinical characteristics, diagnosis and treatment strategies, and prognostic factors in 47 patients with pulmonary mucormycosis[J]. Chin J Intern Med, 2026, 65(7): 734-742.
|
| 17. |
Powell C, Puig CA, Saddoughi SA, et al. Pulmonary mucormycosis: outcomes by treatment modality and underlying comorbidity[J]. Ann Thorac Surg, 2026, 122(2): 311-319.
|
| 18. |
Han Y, Li Y, Liu Z, et al. Surgical therapy for pulmonary aspergillomas and mucormycosis: a 15-year experience from a single clinical center[J/OL]. JTCVS Open, 2026, 31: 101688. DOI: 10.1016/j.xjon.2026.101688.
|
| 19. |
Choi H, Lee H, Jeon K, et al. Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis[J]. J Thorac Dis, 2019, 11(3): 892-900.
|
| 20. |
Multani A, Reveron-Thornton R, Garvert DW, et al. Cut it out! Thoracic surgeon's approach to pulmonary mucormycosis and the role of surgical resection in survival[J]. Mycoses, 2019, 62(10): 893-907.
|
| 21. |
Pulle MV, Puri HV, Asaf BB, et al. Outcomes of early anti-fungal therapy with aggressive surgical resection in pulmonary mucormycosis[J]. Lung India, 2021, 38(4): 314-320.
|
| 22. |
Benjamin SR, Narayanan D, Chandy ST, et al. Pulmonary mucormycosis-a case series[J]. Indian J Thorac Cardiovasc Surg, 2022, 38(2): 177-182.
|
| 23. |
Pulle MV, Bishnoi S, Asaf BB, et al. COVID associated pulmonary mucormycosis: outcomes of surgical therapy[J]. Asian Cardiovasc Thorac Ann, 2023, 31(2): 133-141.
|
| 24. |
朱建坤, 孟倩, 孔康寶, 等. 全肺切除術在肺毛霉菌病治療中的價值[J]. 中國防癆雜志, 2025, 47(3): 274-281.Zhu JK, Meng Q, Kong KB, et al. The value of pneumonectomy in the treatment of pulmonary mucormycosis[J]. Chin J Antituberc, 2025, 47(3): 274-281.
|
| 25. |
von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies[J]. BMJ, 2007, 335(7624): 806-808.
|
| 26. |
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the EORTC and the MSGERC[J]. Clin Infect Dis, 2020, 71(6): 1367-1376.
|
| 27. |
中華醫學會內科學分會臨床指南工作委員會. 氣道腔內球囊封堵治療咯血專家共識(2025版)[J]. 中華內科雜志, 2025, 64(11): 1055-1064.Clinical Guidelines Committee of Internal Medicine of Chinese Medical Association. Expert consensus on endobronchial balloon occlusion in the treatment of hemoptysis (2025 edition)[J]. Chin J Intern Med, 2025, 64(11): 1055-1064.
|
| 28. |
Wang L, Peng W, Zhao Z, et al. Prevalence and treatment of diabetes in China, 2013-2018[J]. JAMA, 2021, 326(24): 2498-2506.
|
| 29. |
Gouzien L, Che D, Cassaing S, et al. Epidemiology and prognostic factors of mucormycosis in France (2012-2022): a cross-sectional study nested in a prospective surveillance programme[J/OL]. Lancet Reg Health Eur, 2024, 45: 101010. DOI: 10.1016/j.lanepe.2024.101010.
|
| 30. |
Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice[J]. J Clin Invest, 2010, 120(6): 1914-1924.
|
| 31. |
Millon L, Caillot D, Berceanu A, et al. Evaluation of serum Mucorales polymerase chain reaction (PCR) for the diagnosis of mucormycoses: the MODIMUCOR prospective trial[J]. Clin Infect Dis, 2022, 75(5): 777-785.
|
| 32. |
Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis[J]. Clin Infect Dis, 2008, 47(4): 503-509.
|
| 33. |
Mammana M, Marulli G, Zuin A, et al. Postpneumonectomy bronchopleural fistula: analysis of risk factors and the role of bronchial stump coverage[J]. Surg Today, 2020, 50(2): 114-122.
|
| 34. |
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis, 2016, 16(7): 828-837.
|
| 35. |
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey[J]. Ann Surg, 2004, 240(2): 205-213.
|